Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis) - PubMed
6 hours ago
- #Psoriasis
- #Deucravacitinib
- #Scalp Psoriasis
- Deucravacitinib showed short-term effectiveness in treating moderate-to-severe psoriasis in a real-world study.
- At week 16, PASI 75, 90, and 100 responses were achieved by 49.6%, 29.7%, and 18.9% of patients, respectively.
- Response rates improved further by week 32, reaching 84.9%, 60.6%, and 45.5% for PASI 75, 90, and 100.
- Among patients with scalp involvement, 89.8% achieved ss-PGA 0/1 at week 16 and 100% by week 32.
- Baseline scalp involvement did not negatively impact overall skin response.
- Deucravacitinib demonstrated a favorable safety profile with mild adverse events reported in 8.1% of patients.
- Treatment discontinuation due to adverse events was low (2.7%), with no severe adverse events observed.
- The study confirms deucravacitinib's therapeutic value, especially in difficult-to-treat areas like scalp psoriasis.